Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Jun;29(3):827-831. doi: 10.19746/j.cnki.issn.1009-2137.2021.03.027.
OBJECTIVE: To investigate the significance of CD27 and CD56 in the prognosis of multiple myeloma (MM) patients, and to establish a simple and convenient prognostic risk score.
METHODS: One hundred and eleven newly diagnosed MM patients treated by bortezomib in Shengjing hospital from January 1, 2013 to January 1, 2019 were selected, and the relationship between clinical characteristics and survival time of patients was analyzed.
RESULTS: The overall survival (OS) of patients in CD27+CD56+ group was longer than that of patients in non-CD27+CD56+ group (P<0.05). β2-microglobulin≥5.5 mmol/L, serum calcium >2.5 mmol/L and expression of non-CD27+CD56+ were the independent risk factors in patients with MM treated by bortezomib.
CONCLUSION: Among patients with MM treated by bortezomib, CD27+CD56+ patients show better prognosis than non-CD27+CD56+ patients. The prognosis of patients with 3 risk factors of β2-MG and serum calcium concentration above the critical value and non-CD27+CD56+ expression is very poor, and clinical trials or hematopoietic stem cell transplantation or other treatment measures should be given as soon as possible.